Your session is about to expire
← Back to Search
Azacitidine + Venetoclax for Acute Myeloid Leukemia
Study Summary
This trial will study how well azacitidine and venetoclax work in treating patients with acute myeloid leukemia.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I agree to use birth control or abstain from sex during and 30 days after treatment.I have an active brain or spinal cord disease.My bone marrow functions well.I have been diagnosed with a specific type of leukemia (APL or AML-M3).I do not have any severe illnesses or social situations that would stop me from following the study's requirements.I can understand and agree to the study's terms.I can join the study at any time if my cancer is still detectable after initial treatment.My organs are functioning well.I am 18 or older with AML in my first remission and not ready for a stem cell transplant.I am not pregnant, breastfeeding, or planning to become pregnant during the study.I have AML with specific genetic changes and can't or won't take certain medications.I am willing to leave my current trial to join a new one.I am a woman of childbearing age and agree to follow specific precautions.I've had intensive therapy for my cancer and am not more than 2 months post my last treatment.I've had at least 2 rounds of mild treatment for my cancer and am now in remission.I have AML without a history of it spreading outside the bone marrow, except for controlled CNS involvement.I am capable of limited self-care and spend more than half of my waking hours out of bed.
- Group 1: Treatment (azacytidine, venetoclax)
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many people are sign ups for this clinical trial?
"The data available on clinicaltrials.gov does show that this particular trial is currently looking for test subjects. This specific study was originally posted on September 13th, 2019 with the most recent update taking place on September 19th, 2020. The investigators running the trial are seeking 50 individuals from a single medical facility."
Can you please tell me what other research has been conducted using Azacitidine?
"350 clinical trials are researching azacitidine with 55 of those in Phase 3. 11282 research sites are studying this treatment for efficacy, many of which are based in Edmonton, Alberta."
Has Azacitidine been cleared by the FDA?
"Azacitidine is still being studied in Phase 2 clinical trials, so there is not enough information to support its efficacy. However, the data that has been collected thus far indicates that it is a safe medication."
For what sorts of illnesses is azacitidine commonly prescribed?
"Azacitidine is a useful medication for induction chemotherapy and treating other conditions such as refractory anemias, leukemia, myelocytic, acute, and multilineage dysplasia."
Are patients being signed up for this experiment currently?
"That is correct. The information available on clinicaltrials.gov indicates that the trial is still looking for participants. This study was originally posted on September 13th, 2019 and has since been updated on September 19th, 2020. They are hoping to find 50 patients from 1 site total."
Share this study with friends
Copy Link
Messenger